All companies › TMCI

TMCI · TREACE MEDICAL CONCEPTS, INC.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys3
Open-market sells0
Total purchased$246,841
Unique insiders buying1
Most senior buyerCEO
Avg price paid$4.41
Research cases0
Last filing2026-08-24

Average price paid is weighted by shares, so a large purchase counts for more than a small one. It is what insiders reported paying, not a target or a fair value.

Insider flow: Buying only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-08-20 — Treace John T. · bought 39,944 @ $4.44 2026-08-21 — Treace John T. · bought 5,000 @ $4.35 2026-08-24 — Treace John T. · bought 11,000 @ $4.34
2026-08-202026-08-24

Insider cost basis

Share-weighted average price across 3 reported purchases, with the full range of prices paid. Purchases only — averaging a sale into an "insider cost" would describe a price nobody paid.

$4.34 $4.44
$4.41 weighted average insider purchase price

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Treace John T. Chief Executive Officer, Director, 10% owner
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $TMCI is the reading of them — and for this company, that is what the list below says it is, no more.

  • Insider cost basisShare-weighted average price paid across the 3 reported purchases, with the full range, against the current price.
  • Insider participationWho bought, how often, and how the buying is distributed across the people filing — one person repeating is not several agreeing.
  • Transaction timelineThe [{'transaction_date': '2026-08-24', 'insider_name': 'Treace John T.', 'insider_title': 'Chief Executive Officer, Director, 10% owner', 'transaction_type': 'Open-market buy', 'shares': 11000.0, 'price': 4.34, 'value': 47740.0, 'is_buy': True}, {'transaction_date': '2026-08-21', 'insider_name': 'Treace John T.', 'insider_title': 'Chief Executive Officer, Director, 10% owner', 'transaction_type': 'Open-market buy', 'shares': 5000.0, 'price': 4.35, 'value': 21750.0, 'is_buy': True}, {'transaction_date': '2026-08-20', 'insider_name': 'Treace John T.', 'insider_title': 'Chief Executive Officer, Director, 10% owner', 'transaction_type': 'Open-market buy', 'shares': 39944.0, 'price': 4.44, 'value': 177351.36, 'is_buy': True}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for TMCI today: no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.